Fluicell Past Earnings Performance

Past criteria checks 0/6

Fluicell's earnings have been declining at an average annual rate of -9.3%, while the Medical Equipment industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 6.5% per year.

Key information

-9.3%

Earnings growth rate

20.0%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate6.5%
Return on equity-167.6%
Net Margin-1,557.5%
Next Earnings Update16 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Fluicell makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:5J9 Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242-29300
31 Dec 233-27290
30 Sep 235-25290
30 Jun 235-22290
31 Mar 234-22290
31 Dec 223-22270
30 Sep 222-20260
30 Jun 223-22260
31 Mar 223-21240
31 Dec 213-22240
30 Sep 213-21240
30 Jun 212-21230
31 Mar 214-19220
31 Dec 205-18200
30 Sep 204-18210
30 Jun 204-17200
31 Mar 203-18200
31 Dec 192-19200
30 Sep 192-18190
30 Jun 192-17180
31 Mar 192-16170
31 Dec 181-15150
30 Sep 182-12130
30 Jun 182-11110
31 Mar 181-990
31 Dec 171-780
31 Dec 163-560
31 Dec 151-320
31 Aug 140-220

Quality Earnings: 5J9 is currently unprofitable.

Growing Profit Margin: 5J9 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 5J9 is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.

Accelerating Growth: Unable to compare 5J9's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5J9 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-6.1%).


Return on Equity

High ROE: 5J9 has a negative Return on Equity (-167.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.